Results 11 to 20 of about 234,058 (316)

Activation of cancer immunotherapy by nanomedicine

Frontiers in Pharmacology, 2022
Cancer is one of the most difficult diseases to be treated in the world. Immunotherapy has made great strides in cancer treatment in recent years, and several tumor immunotherapy drugs have been approved by the U.S. Food and Drug Administration. Currently, immunotherapy faces many challenges, such as lacking specificity, cytotoxicity, drug resistance ...
Lijuan Wang, Henan Xu, Lili Weng, Jin Sun, Ye Jin, Chunping Xiao   +5 more
openaire   +3 more sources

Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma [PDF]

, 2019
Background: Sublingual allergen immunotherapy (SLIT) has been demonstrated to be both clinically efficacious and safe. However, in line with the current regulatory guidance from the European Medicines Agency, allergen immunotherapy (AIT) products must ...
Bachert, Claus, Boot, Johan D, de Kam, Pieter-Jan, Džupinová, Mária, Klimek, Ludger, Kuna, Piotr, Opstelten, Dirk Jan E, Panzner, Petr, Pfaar, Oliver, van Nimwegen, Maroesja J, Yu, Donghui   +10 more
core   +2 more sources

Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. [PDF]

, 2015
BackgroundMultiple system atrophy (MSA) is a neurodegenerative disease characterized by parkinsonism, ataxia and dysautonomia. Histopathologically, the hallmark of MSA is the abnormal accumulation of alpha-synuclein (α-syn) within oligodendroglial cells,
Adame, Anthony, Mandler, Markus, Mante, Michael, Masliah, Eliezer, Mattner, Frank, Patrick, Christina, Rockenstein, Edward, Santic, Radmila, Schmidhuber, Sabine, Schmidt, Walter, Schneeberger, Achim, Valera, Elvira, Weninger, Harald   +12 more
core   +2 more sources

Pharmacological Activation of cGAS for Cancer Immunotherapy [PDF]

Frontiers in Immunology, 2021
When compartmentally mislocalized within cells, nucleic acids can be exceptionally immunostimulatory and can even trigger the immune-mediated elimination of cancer. Specifically, the accumulation of double-stranded DNA in the cytosol can efficiently promote antitumor immunity by activating the cGAMP synthase (cGAS) / stimulator of interferon genes ...
Kyle M. Garland, Jonah C. Rosch, Carcia S. Carson, Lihong Wang-Bishop, Ann Hanna, Sema Sevimli, Casey Van Kaer, Justin M. Balko, Justin M. Balko, Manuel Ascano, John T. Wilson, John T. Wilson, John T. Wilson, John T. Wilson, John T. Wilson, John T. Wilson   +15 more
openaire   +3 more sources

Potential role of immunotherapy in advanced non-small-cell lung cancer [PDF]

, 2016
Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib ...
Antoniou, Georgios, Catarina, Paulo Esrom, De Mello, Ramon Andrade, Nadine, Sara, Veloso, Ana Flavia   +4 more
core   +3 more sources

Economic consequences in real life of allergen immunotherapy in asthma, rhinitis and dermatitis

Revista Alergia México, 2016
Background: Allergen immunotherapy has proved effective in the treatment of various allergies, but whether the clinical benefits outweigh the economic costs has been little evaluated.
Jorge Sánchez, Andrés Sánchez, Ricardo Cardona   +2 more
doaj   +1 more source

Immunological backbone of uveal melanoma: is there a rationale for immunotherapy? [PDF]

, 2019
No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors.
Alessandra Cassano, Apte, Bill, Blom, Brigida Anna Maiorano, De Vries, Durie, Emilio Bria, Ericsson, Ernesto Rossi, Giampaolo Tortora, Gianluigi Petrone, Giovanni Schinzari, Guido Rindi, Ilaria Grazia Zizzari, Lagouros, Makitie, Maria Antonietta Blasi, Maria Grazia Sammarco, Marianna Nuti, Monica Maria Pagliara, Shaw, Sohn, Vincenzo Fiorentino, Whelchel   +24 more
core   +1 more source

A STING-activating nanovaccine for cancer immunotherapy [PDF]

Nature Nanotechnology, 2017
The generation of tumour-specific T cells is critically important for cancer immunotherapy. A major challenge in achieving a robust T-cell response is the spatiotemporal orchestration of antigen cross-presentation in antigen-presenting cells with innate stimulation.
Min Luo, Hua Wang, Zhaohui Wang, Haocheng Cai, Zhigang Lu, Yang Li, Mingjian Du, Gang Huang, Chensu Wang, Xiang Chen, Matthew R. Porembka, Jayanthi Lea, Arthur E. Frankel, Yang-Xin Fu, Zhijian J. Chen, Jinming Gao   +15 more
openaire   +2 more sources

Immunotherapy for B-cell lymphoma: current status and prospective advances

Frontiers in Immunology, 2012
Therapy for non-Hodgkin's lymphoma has progressed significantly over the last decades. However, the majority of patients remain incurable, and novel therapies are needed.
Nurit eHollander
doaj   +1 more source

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [PDF]

, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
Abdallah, K., Anderson, J., Andrews, S., Arrindell, D., Ballesteros, J., Bingham, C. O., Boyer, J., Brogdon, C., Chen, D., Chonzi, D., Cotarla, I., Cunha, R., Dadu, R., Davies, M., Dawson, M., Diab, A., Dicker, Adam, Eifler, L., Ernstoff, M. S., Ferguson, A., Ferlini, C., Frankel, S., Go, W., Gochett, C., Goldberg, J., Goncalves, P., Goswami, T., Gregory, N., Gulley, J. L., Hamad, L., Hayreh, V., Helie, N., Holmes, W., Hsu, J. Y., Ibrahim, R., Kaufman, H. L., Kim, S., Lacouture, M. E., Lambotte, O., Larocca, C., LeBoeuf, N. R., Lehman, K., Lenihan, D., Ley-Acosta, S., Luke, J., McClure, J., Michelon, E., Nakamura, M., Onofrei, C., Patel, K., Piperdi, B., Puzanov, I., Rasheed, Z., Reshef, D., Riemer, J., Robert, C., Sarkeshik, M., Saylors, A., Schreiber, J., Shafer-Weaver, K., Shannon, V., Sharfman, W., Sharma, R., Sharon, E., Sherry, R., Silk, A. W., Simonson, C., Skondra, D., Suarez-Almazor, M. E., Thomas, C., Thompson, J. A., Trehu, E., Tresnan, D., Turner, M., Wang, Y., Wariabharaj, D., Waxman, I., Wiley, K., Wood, L., Zhang, L., Zheng, P.   +80 more
core   +2 more sources